Search

Your search keyword '"Fayad, Luis E."' showing total 665 results
Start Over Author "Fayad, Luis E."
665 results on '"Fayad, Luis E."'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

2. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Author

Stein-Thoeringer, Christoph K., Saini, Neeraj Y., Zamir, Eli, Blumenberg, Viktoria, Schubert, Maria-Luisa, Mor, Uria, Fante, Matthias A., Schmidt, Sabine, Hayase, Eiko, Hayase, Tomo, Rohrbach, Roman, Chang, Chia-Chi, McDaniel, Lauren, Flores, Ivonne, Gaiser, Rogier, Edinger, Matthias, Wolff, Daniel, Heidenreich, Martin, Strati, Paolo, Nair, Ranjit, Chihara, Dai, Fayad, Luis E., Ahmed, Sairah, Iyer, Swaminathan P., Steiner, Raphael E., Jain, Preetesh, Nastoupil, Loretta J., Westin, Jason, Arora, Reetakshi, Wang, Michael L., Turner, Joel, Menges, Meghan, Hidalgo-Vargas, Melanie, Reid, Kayla, Dreger, Peter, Schmitt, Anita, Müller-Tidow, Carsten, Locke, Frederick L., Davila, Marco L., Champlin, Richard E., Flowers, Christopher R., Shpall, Elizabeth J., Poeck, Hendrik, Neelapu, Sattva S., Schmitt, Michael, Subklewe, Marion, Jain, Michael D., Jenq, Robert R., and Elinav, Eran

Published
2023
Full Text
View/download PDF

4. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

5. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Author

van Rhee, Frits, Casper, Corey, Voorhees, Peter M, Fayad, Luis E, Gibson, Damilola, Kanhai, Karan, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Castleman Disease, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

BACKGROUND:Siltuximab is recommended by international consensus as a first-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety data. This study was done to assess the long-term safety and activity of siltuximab over up to 6 years of treatment. METHODS:This study is a prespecified open-label extension analysis of a phase 1 trial (NCT00412321) and a phase 2 trial (NCT01024036), done at 26 hospitals worldwide. Patients in both studies were at least 18 years old with histologically confirmed, symptomatic Castleman disease. This extension study enrolled 60 patients who completed the previous trials without disease progression on siltuximab. Patients received siltuximab infusions of 11 mg/kg every 3 weeks (which could be extended to 6 weeks) for up to 6 years. Descriptive statistics were used to summarise the data. No formal hypothesis testing was performed. The primary endpoint was the safety of siltuximab, assessed at each dosing cycle. The study was registered with ClinicalTrials.gov, number NCT01400503 and with EudraCT, number 2010-022837-27. FINDINGS:Patient enrolment into the phase 1 trial was from June 20, 2005, to Sept 15, 2009, and enrolment into the phase 2 trial was from Feb 9, 2010, to Feb 3, 2012. Patients were enrolled in this long-term extension from April 1, 2011, to Jan 15, 2014. Median follow-up was 6 years (IQR 5·11-7·76). Median treatment duration, from the beginning of the previous trials to the end of the present study, was 5·5 years (IQR 4·26-7·14). Siltuximab was well tolerated; however, adverse events of grade 3 or worse were reported in 36 (60%) of 60 patients with the most common being hypertension (eight [13%]), fatigue (five [8%]), nausea (four [7%]), neutropenia (four [7%]), and vomiting (three [5%]). 25 (42%) patients reported at least one serious adverse event, which most commonly was an infection (eight [13%]). Only two serious adverse events, polycythaemia and urinary retention, were considered related to siltuximab treatment. 18 patients discontinued before study completion, either to receive siltuximab locally (eight) or because of progressive disease (two), adverse events (two), or other reasons (six). No deaths were reported. INTERPRETATION:These results show that siltuximab is well tolerated long term and provides important evidence for the feasibility of the life-long use required by patients with idiopathic multicentric Castleman disease. FUNDING:Janssen R&D and EUSA Pharma.

Published
2020

6. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Author

Fahrmann, Johannes F., Saini, Neeraj Y., Chia-Chi, Chang, Irajizad, Ehsan, Strati, Paolo, Nair, Ranjit, Fayad, Luis E., Ahmed, Sairah, Lee, Hun Ju, Iyer, Swaminathan, Steiner, Raphael, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B., Nastoupil, Loretta, Jain, Preetesh, Wang, Michael, Green, Michael, Westin, Jason, Blumenberg, Viktoria, Davila, Marco, Champlin, Richard, Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Christopher R., Jain, Michael, Jenq, Robert, Stein-Thoeringer, Christoph K., Subklewe, Marion, Neelapu, Sattva S., and Hanash, Sam

Published
2022
Full Text
View/download PDF

7. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher R., Tummala, Sudhakar, Ramdial, Jeremy L., Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2021
Full Text
View/download PDF

8. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

9. Can we cure refractory Hodgkin’s lymphoma with transplantation?

Author

Ciurea, Stefan O., Kongtim, Piyanuch, Srour, Samer, Saini, Neeraj, Im, Jin, Ramdial, Jeremy, Khouri, Issa, Anderlini, Paolo, Popat, Uday, Hosing, Chitra, Champlin, Richard E., Lee, Hun J., Fayad, Luis E., Hagemeister, Fredrick B., Bica, Ana M., Lipan, Lavinia, Craciun, Oana, Jercan, Cristina G., Tanase, Alina, and Colita, Anca

Published
2021
Full Text
View/download PDF

10. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

11. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

Author

Strati, Paolo, primary, Jallouk, Andrew, additional, Deng, Qing, additional, Li, Xubin, additional, Feng, Lei, additional, Sun, Ryan, additional, Adkins, Sherry, additional, Johncy, Swapna, additional, Cain, Taylor, additional, Steiner, Raphael E., additional, Ahmed, Sairah, additional, Chihara, Dai, additional, Fayad, Luis E., additional, Iyer, Swaminathan P., additional, Horowitz, Sandra, additional, Nastoupil, Loretta J., additional, Nair, Ranjit, additional, Hassan, Ahmed, additional, Daoud, Taher E., additional, Hawkins, Misha, additional, Rodriguez, Maria A., additional, Shpall, Elizabeth J., additional, Ramdial, Jeremy L., additional, Kebriaei, Partow, additional, Hong, David S., additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

12. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Author

Zelenetz, Andrew D., primary, Gordon, Leo I., additional, Abramson, Jeremy S., additional, Advani, Ranjana H., additional, Andreadis, Babis, additional, Bartlett, Nancy L., additional, Budde, L. Elizabeth, additional, Caimi, Paolo F., additional, Chang, Julie E., additional, Christian, Beth, additional, DeVos, Sven, additional, Dholaria, Bhagirathbhai, additional, Fayad, Luis E., additional, Habermann, Thomas M., additional, Hamid, Muhammad Saad, additional, Hernandez-Ilizaliturri, Francisco, additional, Hu, Boyu, additional, Kaminski, Mark S., additional, Karimi, Yasmin, additional, Kelsey, Christopher R., additional, King, Rebecca, additional, Krivacic, Susan, additional, LaCasce, Ann S., additional, Lim, Megan, additional, Messmer, Marcus, additional, Narkhede, Mayur, additional, Rabinovitch, Rachel, additional, Ramakrishnan, Praveen, additional, Reid, Erin, additional, Roberts, Kenneth B., additional, Saeed, Hayder, additional, Smith, Stephen D., additional, Svoboda, Jakub, additional, Swinnen, Lode J., additional, Tuscano, Joseph, additional, Vose, Julie M., additional, Dwyer, Mary A., additional, and Sundar, Hema, additional

Published
2023
Full Text
View/download PDF

14. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

Author

van Rhee, Frits, Casper, Corey, Voorhees, Peter M, Fayad, Luis E, van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Cardiovascular, Cancer, Clinical Research, Patient Safety, 7.1 Individual care needs, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Castleman Disease, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Time Factors, Treatment Outcome, United States, Young Adult, multi-centric Castleman's disease, interleukin-6, siltuximab, clinical trial, Oncology and Carcinogenesis, Oncology and carcinogenesis
Abstract

BACKGROUND:Multicentric Castleman disease (MCD) is a rare, systemic lymphoproliferative disorder driven by interleukin (IL)-6 overproduction. Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled study of MCD. METHODS:This preplanned safety analysis was conducted to evaluate the long-term safety of siltuximab treatment among 19 patients with MCD who had stable disease or better and were enrolled in a phase-1 study and subsequent ongoing, open-label, phase-2 extension study. Dosing was 11 mg/kg administered intravenously every 3 weeks, per protocol, or every 6 weeks at the investigator's discretion. Safety monitoring focused on potential risks associated with the anti-IL-6 mechanism of action. Investigator-assessed disease control status was also documented. RESULTS:Median treatment duration for the 19 patients was 5.1 (range 3.4, 7.2) years, with 14 (74%) patients treated for >4 years. Grade-≥ 3 adverse events (AEs) reported in >1 patient included hypertension (n = 3) and nausea, cellulitis, and fatigue (n = 2 each). Grade-≥ 3 AEs at least possibly attributed to siltuximab were leukopenia, lymphopenia, and a serious AE of polycythemia (n = 1 each). Hypertriglyceridemia and hypercholesterolemia (total cholesterol) were reported in 8 and 9 patients, respectively. No disease relapses were observed, and 8 of 19 patients were able to switch to an every-6-week dosing schedule. CONCLUSIONS:All MCD patients in this extension study have received siltuximab for a prolonged duration (up to 7 years) without evidence of cumulative toxicity or treatment discontinuations and with few serious infections. All patients are alive, demonstrate sustained disease control, and continue to receive siltuximab.

Published
2015

15. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

17. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

18. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan P., additional, Nastoupil, Loretta J., additional, Hagemeister, Frederick B., additional, Parra, Edwin R., additional, Saini, Neeraj, additional, Takahashi, Koichi, additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

20. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma

Author

Milgrom, Sarah A., Pinnix, Chelsea C., Chi, T. Linda, Vu, Thinh H., Gunther, Jillian R., Sheu, Tommy, Fowler, Nathan, Westin, Jason R., Nastoupil, Loretta J., Oki, Yasuhiro, Fayad, Luis E., Neelapu, Sattva, Rodriguez, Maria Alma, Hagemeister, Frederick B., Fanale, Michelle A., Lee, Hun J., Hosing, Chitra, Ahmed, Sairah, Nieto, Yago, Shpall, Elizabeth J., and Dabaja, Bouthaina S.

Published
2018
Full Text
View/download PDF

21. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Author

Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L.Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F.B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., and Younes, Anas

Published
2017
Full Text
View/download PDF

22. Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

24. Figure A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma

Author

Chahoud, Jad, primary, Sui, Dawen, primary, Erwin, William D., primary, Gulbis, Alison M., primary, Korbling, Martin, primary, Zhang, Mingzhi, primary, Ahmed, Sairah, primary, Alatrash, Gheath, primary, Anderlini, Paolo, primary, Ciurea, Stefan O., primary, Oran, Betul, primary, Fayad, Luis E., primary, Bassett, Roland L., primary, Jabbour, Elias J., primary, Medeiros, L. Jeffrey, primary, Macapinlac, Homer A., primary, Young, Ken H., primary, and Khouri, Issa F., primary

Published
2023
Full Text
View/download PDF

25. Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

28. Table A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma

Author

Chahoud, Jad, primary, Sui, Dawen, primary, Erwin, William D., primary, Gulbis, Alison M., primary, Korbling, Martin, primary, Zhang, Mingzhi, primary, Ahmed, Sairah, primary, Alatrash, Gheath, primary, Anderlini, Paolo, primary, Ciurea, Stefan O., primary, Oran, Betul, primary, Fayad, Luis E., primary, Bassett, Roland L., primary, Jabbour, Elias J., primary, Medeiros, L. Jeffrey, primary, Macapinlac, Homer A., primary, Young, Ken H., primary, and Khouri, Issa F., primary

Published
2023
Full Text
View/download PDF

32. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Author

Oki, Yasuhiro, Ewer, Michael S., Lenihan, Daniel J., Fisch, Michael J., Hagemeister, Fredrick B., Fanale, Michelle, Romaguera, Jorge, Pro, Barbara, Fowler, Nathan, Younes, Anas, Astrow, Alan B., Huang, Xuelin, Kwak, Larry W., Samaniego, Felipe, McLaughlin, Peter, Neelapu, Sattva S., Wang, Michael, Fayad, Luis E., Durand, Jean-Bernard, and Alma Rodriguez, M.

Published
2015
Full Text
View/download PDF

33. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Author

Jallouk, Andrew P., primary, Gouni, Sushanth, additional, Westin, Jason, additional, Feng, Lei, additional, Mistry, Haleigh, additional, Steiner, Raphael E, additional, James, Jinsu, additional, Noorani, Mansoor, additional, Horowitz, Sandra, additional, Puebla-Osorio, Nahum, additional, Fayad, Luis E, additional, Iyer, Swaminathan P., additional, Hawkins, Misha, additional, Flowers, Christopher R, additional, Ahmed, Sairah, additional, Nastoupil, Loretta J, additional, Kebriaei, Partow, additional, Shpall, Elizabeth J, additional, Neelapu, Sattva S, additional, Nieto, Yago, additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

35. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

37. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

Author

Dabaja, Bouthaina S., Hess, Kenneth, Shihadeh, Ferial, Podoloff, Donald A., Medeiros, L. Jeffrey, Mawlawi, Osama, Arzu, Isidora, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis E., Reed, Valerie K., Kedir, Aziza, Wogan, Christine F., and Rodriguez, Alma

Published
2014
Full Text
View/download PDF

38. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Author

Westin, Jason R, Chu, Fuliang, Zhang, Min, Fayad, Luis E, Kwak, Larry W, Fowler, Nathan, Romaguera, Jorge, Hagemeister, Fredrick, Fanale, Michelle, Samaniego, Felipe, Feng, Lei, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Ma, Wencai, Gao, Yanli, Wallace, Michael, Vence, Luis M, Radvanyi, Laszlo, Muzzafar, Tariq, Rotem-Yehudar, Rinat, Davis, R Eric, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

41. Early‐stage Hodgkin lymphoma outcomes after combined modality therapy according to the post‐chemotherapy 5‐point score: can residual pet‐positive disease be cured with radiotherapy alone?

Author

Milgrom, Sarah A., Pinnix, Chelsea C., Chuang, Hubert, Oki, Yasuhiro, Akhtari, Mani, Mawlawi, Osama, Garg, Naveen, Gunther, Jillian R., Reddy, Jay P., Smith, Grace L., Rohren, Eric, Hagemeister, Frederick B., Lee, Hun J., Fayad, Luis E., Dong, Wenli, Osborne, Eleanor M., Abou Yehia, Zeinab, Fanale, Michelle, and Dabaja, Bouthaina S.

Published
2017
Full Text
View/download PDF

42. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Author

Westin, Jason R., Thompson, Michael A., Cataldo, Vince D., Fayad, Luis E., Fowler, Nathan, Fanale, Michelle A., Neelapu, Saatva, Samaniego, Felipe, Romaguera, Jorge, Shah, Jatin, McLaughlin, Peter, Pro, Barbara, Kwak, Larry W., Sanjorjo, Perpetua, Murphy, William A., Jimenez, Camillo, Toth, Bela, Dong, Wenli, and Hagemeister, Fredrick B.

Published
2013
Full Text
View/download PDF

44. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

45. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Author

Younes, Anas, Oki, Yasuhiro, McLaughlin, Peter, Copeland, Amanda R., Goy, Andre, Pro, Barbara, Feng, Lei, Yuan, Ying, Chuang, Hubert H., Macapinlac, Homer A., Hagemeister, Fredrick, Romaguera, Jorge, Samaniego, Felipe, Fanale, Michelle A., Dabaja, Bouthaina Shbib, Rodriguez, Maria A., Dang, Nam, Kwak, Larry W., Neelapu, Sattva S., and Fayad, Luis E.

Published
2012
Full Text
View/download PDF

47. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario Luiz, additional, Henderson, Jared, additional, Balada, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan, additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael, additional

Published
2022
Full Text
View/download PDF

49. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Author

Gouni, Sushanth, primary, Westin, Jason R., additional, Mistry, Haleigh, additional, Steiner, Raphael Eric, additional, James, Jinsu, additional, Parmar, Simrit, additional, Noorani, Mansoor, additional, Fowler, Nathan H., additional, Horowitz, Sandra B., additional, Feng, Lei, additional, Fayad, Luis E., additional, Iyer, Swaminathan P, additional, Green, Michael R, additional, Hawkins, Misha, additional, Flowers, Christopher R., additional, Ahmed, Sairah, additional, Nastoupil, Loretta, additional, Neelapu, Sattva S., additional, Nieto, Yago, additional, and Strati, Paolo, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results